Table 1.
Allo-HCT | Control | |
---|---|---|
(n = 17) | (n = 12) | |
Sex, % male | 70% | 42% |
Age, years | 45 ± 18 | 43 ± 13 |
Weight, kg | 80.7 ± 18.0 | 74.3 ± 14.4 |
Body mass index, kg.m −2 | 27.4 ± 6.2 | 24.6 ± 3.7 |
Cardiovascular function | ||
LVEF, % | 54.7 ± 5.5* | 59.5 ± 5.7* |
GLS, % | −17.8 ± 2.0* | −20.0 ± 2.4 |
CI Reserve, L.min−1.m−2 | 3.8 ± 1.4** | 5.9 ± 1.7 |
VO2peak, ml.kg−1.min−1 | 22.9 ± 8.0*** | 34.8 ± 8.1 |
VO2peak, % predicted | 67 ± 12*** | 104 ± 16 |
Functional disability, n (%) | 5 (29) | 0 (0) |
Cardiovascular risk factors, n (%) | ||
Hypertension | 4 (24) | 0 (0) |
Hyperlipidaemia | 2 (12) | 0 (0) |
Diabetes | 1 (6) | 0 (0) |
Body mass index ≥25 kg.m−2 | 9 (53) | 5 (42) |
Previous cardiovascular event | 2 (12) | 0 (0) |
≥1 cardiovascular risk factor | 10 (59) | 5 (42) |
Cardiovascular medications, n (%) | ||
Statin/Cholesterol absorption inhibitor | 1 (6) | 0 (0) |
Antihypertensives | 2 (12) | 0 (0) |
Beta–blocker | 1 (6) | 0 (0) |
Antidiabetic | 1 (6) | 0 (0) |
Non–steroidal anti–inflammatory | 3 (18) | 1 (8) |
Diagnosis, n (%) | ||
Acute myeloid leukemia | 11 (65) | n/a |
Non–Hodgkin lymphoma | 3 (18) | n/a |
Acute lymphoblastic leukemia | 2 (12) | n/a |
Myelodysplasia | 1 (6) | n/a |
Prior cancer treatment, n (%) | ||
No prior treatment | 1 (6) | n/a |
Chemotherapy | 16 (94) | n/a |
Cumulative anthracycline dose, mg.m−2 | 180 (100−270) | n/a |
Targeted Therapy | 5 (29) | n/a |
Immunotherapy | 3 (18) | n/a |
Radiation | 2 (12) | n/a |
Autologous stem cell transplant | 1 (6) | n/a |
Data are mean ± SD, median (IQR) or n (%). CI, cardiac index; GLS, global longitudinal strain; LVEF, left-ventricular ejection fraction; VO2peak, peak oxygen uptake. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control.